Loading
Thyroid cancer that no longer takes up radioactive iodine, or keeps growing despite it. This is when kinase inhibitor pills come in.
Defined by absence of uptake on a diagnostic scan, progression within 12 months of treatment, or cumulative activity >22.2 GBq (600 mCi) without control. Affects ~5-15% of differentiated thyroid cancers, often with BRAF V600E or TERT promoter mutations. Median survival historically 3-5 years; lenvatinib, sorafenib, and genotype-directed drugs (RET, NTRK, BRAF) apply.
Showing the technology this term belongs to: Radioiodine therapy and whole-body iodine scanning.
Shares SELECT, Follicular thyroid cancer, Papillary thyroid cancer.
Shares Radioactive iodine (I-131), Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
Shares MAPK inhibitor redifferentiation → radioiodine, Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
Shares Radioactive iodine (I-131), Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
Shares DECISION, Follicular thyroid cancer.
Shares Follicular thyroid cancer, Papillary thyroid cancer, Thyroid cancer.
Shares DECISION, Thyroid cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/